================================================================================
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported):
February 13, 2007
TRANSGENOMIC, INC.
------------------------------------------------------
(Exact name of registrant as specified in its charter)
Delaware 000-30975 911789357
- ------------------------ ------------------------ ----------------------
(State of Incorporation) (Commission File Number) (IRS Employer
Identification Number)
12325 Emmet Street, Omaha, Nebraska 68164
---------------------------------------- ----------
(Address of principal executive offices) (Zip Code)
(402) 452-5400
----------------------------------------------------
(Registrant's telephone number, including area code)
Not applicable
-------------------------------------------------------------
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions:
[ ] Written communications pursuant to Rule 425 under the Securities
Act (17 CFR 230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange
Act (17 CFR 240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the
Exchange Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the
Exchange Act (17 CFR 240.13e-4(c))
================================================================================
ITEM 3.01. NOTICE OF DELISTING OR FAILURE TO SATISFY A CONTINUED LISTING RULE
OR STANDARD; TRANSFER OF LISTING
On February 13, 2007, Transgenomic, Inc. (the "Registrant") received a
staff determination letter from Nasdaq's Listing Qualifications Department
indicating that the Registrant no longer met the minimum bid price requirement
for continued listing on the Nasdaq Capital Market ("Capital Market") as set
forth in Marketplace Rule 4310(c)(4). As a result, the Registrant's common stock
is subject to delisting from the Capital Market. Trading in the Registrant's
common stock will be suspended on the Capital Market at the opening of business
on February 22, 2007, and a Form 25-NSE will be filed with the Securities and
Exchange Commission which will remove the Registrant's common stock from listing
and registration on the Capital Market. The Registrant does not intend to appeal
this determination. The Registrant has been advised that Feltl & Company has
made an application to register and quote the Registrant's common stock on the
OTC Bulletin Board.
ITEM 9.01. FINANCIAL STATEMENTS AND EXHIBITS
99.1 Press Release, dated February 20, 2007, announcing that the Registrant
has received notice of delisting from the Nasdaq Capital Market.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as
amended, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
Dated: February 20, 2007 TRANSGENOMIC, INC.
By: /s/ Debra Schneider
-----------------------
Debra Schneider,
Chief Financial Officer